Cook Medical said today that it inked a collaborative deal with South Korean Taewoong Medical to distribute a selection of the company’s stents in the U.S.

The deal includes Taewoong’s Niti-S Through The Scope esophageal stent, which is the flagship product of the company’s Niti-S self-expandable line of metal gastrointestinal stents, Cook said.

The Niti-S TTS esophageal stent is intended for use in treating certain esophageal strictures caused by malignant tumors, Bloomington, Ind.-based Cook Medical said. The system is deployed through a 10.5 French delivery system which Cook said is unique to the U.S. market, and allows the system to be introduced and placed through a scope with a conical tip intended to navigate through tight strictures and tortuous anatomies.

“We are very pleased and proud to enter into this collaboration with Cook Medical, a leading global medical device company. We believe Cook Medical’s philosophy and focus towards continuous innovation in product development is akin to Taewoong Medical’s own philosophy. And I am confident that our partnership will bring the optimal stent solutions to our U.S. doctors and patients,” Taewoong Medical CEO Kyongmin Shin said in a press release.

Cook Medical said that in addition to the Niti-S TTS stent, it will also distribute the standard non-TTS version of the stent, as well as the Niti-S biliiary stent.

“We’re excited to now be offering these stents and to continue our focus in supporting physicians in their treatment of diseases of the GI tract by adding Taewoong’s stent technologies to our existing Evolution and Zilver stent offerings. In addition, we’re honored to collaborate with Taewoong because we share a commitment to provide solutions that deliver patient care through innovation,” Cook Medical endoscopy biz VP Barry Slowey said in a prepared release.

In September, Cook Medical said that the FDA closed out a 2014 warning letter it sent to the company over quality system issues with its Bloomington, Ind.-based manufacturing facilities.